File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparisons of alloreactive potential of clinical hematopoietic grafts

TitleComparisons of alloreactive potential of clinical hematopoietic grafts
Authors
Issue Date1999
Citation
Transplantation, 1999, v. 68, n. 5, p. 628-635 How to Cite?
AbstractBackground. We sought to compare the immunoreactive potential of human cord blood (CB) versus normal adult bone marrow (BM) versus mobilized blood (peripheral blood stem cells; PBSC) from cancer patients. Methods. Forty mice were randomized to receive a range of doses of T cell-replete cell preparations from one of the above three cell sources. Twenty-eight control mice underwent transplantation with T cell-depleted cells. Mice were observed for 60 days for the development of fatal xenogeneic graft-versus-host disease-like syndrome (GVHDLS). Results. For the mice that had received T cell-replete grafts of CB or BM or PBSC, the duration of GVHDLS free survival of the chimeras was inversely proportional to the number of T cells transplanted. After adjustment for the number of T cells transplanted, the relative hazard of developing fatal GVHDLS was 62-fold higher for PBSC and 210-fold higher for BM as compared with CB. Flow cytometric and histologic analyses of selected chimeras that died of GVHDLS showed extensive proliferation of human T cells in multiple organs. In contrast, mice that survived to day 60 were engrafted with human myeloid and B lymphoid cells. Conclusions. The immunoreactive potential, as measured by this in vivo assay, differed among clinical grafts: BM > PBSC > CB.
Persistent Identifierhttp://hdl.handle.net/10722/294395
ISSN
2023 Impact Factor: 5.3
2023 SCImago Journal Rankings: 1.371
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLeung, Wing-
dc.contributor.authorRamírez, Manuel-
dc.contributor.authorMukherjee, Goutam-
dc.contributor.authorPerlman, Elizabeth J.-
dc.contributor.authorCivin, Curt I.-
dc.date.accessioned2020-12-03T08:22:38Z-
dc.date.available2020-12-03T08:22:38Z-
dc.date.issued1999-
dc.identifier.citationTransplantation, 1999, v. 68, n. 5, p. 628-635-
dc.identifier.issn0041-1337-
dc.identifier.urihttp://hdl.handle.net/10722/294395-
dc.description.abstractBackground. We sought to compare the immunoreactive potential of human cord blood (CB) versus normal adult bone marrow (BM) versus mobilized blood (peripheral blood stem cells; PBSC) from cancer patients. Methods. Forty mice were randomized to receive a range of doses of T cell-replete cell preparations from one of the above three cell sources. Twenty-eight control mice underwent transplantation with T cell-depleted cells. Mice were observed for 60 days for the development of fatal xenogeneic graft-versus-host disease-like syndrome (GVHDLS). Results. For the mice that had received T cell-replete grafts of CB or BM or PBSC, the duration of GVHDLS free survival of the chimeras was inversely proportional to the number of T cells transplanted. After adjustment for the number of T cells transplanted, the relative hazard of developing fatal GVHDLS was 62-fold higher for PBSC and 210-fold higher for BM as compared with CB. Flow cytometric and histologic analyses of selected chimeras that died of GVHDLS showed extensive proliferation of human T cells in multiple organs. In contrast, mice that survived to day 60 were engrafted with human myeloid and B lymphoid cells. Conclusions. The immunoreactive potential, as measured by this in vivo assay, differed among clinical grafts: BM > PBSC > CB.-
dc.languageeng-
dc.relation.ispartofTransplantation-
dc.titleComparisons of alloreactive potential of clinical hematopoietic grafts-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1097/00007890-199909150-00006-
dc.identifier.pmid10507480-
dc.identifier.scopuseid_2-s2.0-0344678346-
dc.identifier.volume68-
dc.identifier.issue5-
dc.identifier.spage628-
dc.identifier.epage635-
dc.identifier.isiWOS:000082939200006-
dc.identifier.issnl0041-1337-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats